arrow
N

Nora Schwegel

university heart center
H指数:6
被引数:93

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The prospective Austrian hypertrophic cardiomyopathy registry – design, methods and results of the run-in period

奥地利肥厚型心肌病前瞻性登记研究——入组期设计、方法和结果

2026-04-150
OAAI
Prognostic value of circulating glypican-4 in chronic heart failure

循环 Glypican-4 的预后价值在慢性心力衰竭中

2026-04-070
OAAI
Simultaneous transcatheter edge-to-edge repair (TEER) for severe mitral and tricuspid regurgitation is feasible, safe, and associated with good clinical outcome

经导管缘对缘修复(TEER)同时治疗严重二尖瓣和三尖瓣反流是可行的、安全的,并且与良好的临床结局相关

2026-02-100
PRE
Impact of Ertugliflozin on Cardiac Structure and Function in Patients with ICDs/CRT-Ds Assessed by Echocardiography: A Post Hoc Sub-Analysis of the ERASe Trial

Ertugliflozin对植入ICD/CRT-D患者心脏结构与功能的影响:基于ERASe试验的事后亚组分析

2025-11-220
OAAI
Impact of empagliflozin on cardiac structure and function assessed by echocardiography after myocardial infarction: a post-hoc sub-analysis of the emmy trial

通过超声心动图评估empagliflozin对心肌梗死后心脏结构和功能的影响: emmy试验的事后子分析

2024-09-160
OAAI
Prevalence and prognostic impact of bone disease in chronic heart failure with reduced ejection fraction

射血分数降低的慢性心力衰竭中骨病的患病率和预后影响

2024-03-073
OA
Low-grade systemic inflammation and left ventricular dysfunction in hypertensive compared to non-hypertensive hypertrophic cardiomyopathy

与非高血压肥厚型心肌病相比,高血压患者的低度全身性炎症和左心功能不全

2024-03-012
OAAI
Non-eligibility for pivotal HFpEF/HFmrEF outcome trials and mortality in a contemporary heart failure cohort

当代心力衰竭队列中关键HFpEF/HFmrEF结果试验的非资格和死亡率

2023-12-013
OA